Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival
Cervical cancer is a global health problem; therapies focused on eliminating tumour cells and strengthening different immunotherapies are in development. However, it has been observed that cervical tumour cells can evade cell death mechanisms and generate immune system molecules to promote their pro...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1543 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846105583340486656 |
|---|---|
| author | Adriana Gutiérrez-Hoya Ivan Ortiz-Garrido Itzel Salazar-Valencia Christopher Romero-Hernández Arturo Valle-Mendiola Benny Weiss-Steider Isabel Soto-Cruz |
| author_facet | Adriana Gutiérrez-Hoya Ivan Ortiz-Garrido Itzel Salazar-Valencia Christopher Romero-Hernández Arturo Valle-Mendiola Benny Weiss-Steider Isabel Soto-Cruz |
| author_sort | Adriana Gutiérrez-Hoya |
| collection | DOAJ |
| description | Cervical cancer is a global health problem; therapies focused on eliminating tumour cells and strengthening different immunotherapies are in development. However, it has been observed that cervical tumour cells can evade cell death mechanisms and generate immune system molecules to promote their proliferation and metastasis. In this context, we analysed the role of the IL-2 and CD95 pathways, essential molecules in activating the immune system and eliminating tumour cells. However, it is important to analyse their role in cervical tumour cells because these cells could be using these pathways to proliferate. In this study, we found that SiHa and HeLa cells respond to treatment, with 10 IU/mL of IL-2 inducing their proliferation and 100 IU/mL of IL-2 decreasing their proliferation. We also observed that they express a high percentage of the CD95 receptor and its ligand (CD95L) and that treatment with CD95 agonist antibodies at low doses increases cell proliferation. Furthermore, simultaneous treatment with high doses of IL-2 plus CD95 agonist antibody positively regulates LC3B accumulation. We did not observe apoptosis under any of the treatments carried out. In conclusion, cervical tumour cells can use the IL-2 and CD95 pathways to induce their proliferation and potentially activate cytoprotective mechanisms for survival. |
| format | Article |
| id | doaj-art-a8098793599f4a34b7cc08a4d8fc46a9 |
| institution | Kabale University |
| issn | 2218-273X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-a8098793599f4a34b7cc08a4d8fc46a92024-12-27T14:13:45ZengMDPI AGBiomolecules2218-273X2024-12-011412154310.3390/biom14121543Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and SurvivalAdriana Gutiérrez-Hoya0Ivan Ortiz-Garrido1Itzel Salazar-Valencia2Christopher Romero-Hernández3Arturo Valle-Mendiola4Benny Weiss-Steider5Isabel Soto-Cruz6Molecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, MexicoMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, MexicoMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, MexicoMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, MexicoMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, MexicoMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, MexicoMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, UMIEZ Campus II FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, MexicoCervical cancer is a global health problem; therapies focused on eliminating tumour cells and strengthening different immunotherapies are in development. However, it has been observed that cervical tumour cells can evade cell death mechanisms and generate immune system molecules to promote their proliferation and metastasis. In this context, we analysed the role of the IL-2 and CD95 pathways, essential molecules in activating the immune system and eliminating tumour cells. However, it is important to analyse their role in cervical tumour cells because these cells could be using these pathways to proliferate. In this study, we found that SiHa and HeLa cells respond to treatment, with 10 IU/mL of IL-2 inducing their proliferation and 100 IU/mL of IL-2 decreasing their proliferation. We also observed that they express a high percentage of the CD95 receptor and its ligand (CD95L) and that treatment with CD95 agonist antibodies at low doses increases cell proliferation. Furthermore, simultaneous treatment with high doses of IL-2 plus CD95 agonist antibody positively regulates LC3B accumulation. We did not observe apoptosis under any of the treatments carried out. In conclusion, cervical tumour cells can use the IL-2 and CD95 pathways to induce their proliferation and potentially activate cytoprotective mechanisms for survival.https://www.mdpi.com/2218-273X/14/12/1543cervical cancerinterleukin-2CD95cell proliferationagonist antibodiesLC3B foci |
| spellingShingle | Adriana Gutiérrez-Hoya Ivan Ortiz-Garrido Itzel Salazar-Valencia Christopher Romero-Hernández Arturo Valle-Mendiola Benny Weiss-Steider Isabel Soto-Cruz Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival Biomolecules cervical cancer interleukin-2 CD95 cell proliferation agonist antibodies LC3B foci |
| title | Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival |
| title_full | Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival |
| title_fullStr | Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival |
| title_full_unstemmed | Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival |
| title_short | Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival |
| title_sort | cervical cancer cells use the cd95 and il 2 pathways to promote their proliferation and survival |
| topic | cervical cancer interleukin-2 CD95 cell proliferation agonist antibodies LC3B foci |
| url | https://www.mdpi.com/2218-273X/14/12/1543 |
| work_keys_str_mv | AT adrianagutierrezhoya cervicalcancercellsusethecd95andil2pathwaystopromotetheirproliferationandsurvival AT ivanortizgarrido cervicalcancercellsusethecd95andil2pathwaystopromotetheirproliferationandsurvival AT itzelsalazarvalencia cervicalcancercellsusethecd95andil2pathwaystopromotetheirproliferationandsurvival AT christopherromerohernandez cervicalcancercellsusethecd95andil2pathwaystopromotetheirproliferationandsurvival AT arturovallemendiola cervicalcancercellsusethecd95andil2pathwaystopromotetheirproliferationandsurvival AT bennyweisssteider cervicalcancercellsusethecd95andil2pathwaystopromotetheirproliferationandsurvival AT isabelsotocruz cervicalcancercellsusethecd95andil2pathwaystopromotetheirproliferationandsurvival |